psilocybin

psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi. Upon ingestion, it is converted by the body into psilocin, which is primarily responsible for its psychoactive effects. These effects can include profound alterations in perception, mood, and thought, often described as mystical or spiritual experiences. The compound has a long history of use in indigenous Mesoamerican cultures and is now the subject of extensive modern clinical research for various psychiatric conditions.

Chemical properties and pharmacology

Psilocybin is classified chemically as a tryptamine alkaloid, sharing a core structural similarity with the neurotransmitter serotonin. It is a prodrug, meaning it is biologically inactive until metabolized in the body. After oral administration, it is rapidly dephosphorylated by the enzyme alkaline phosphatase into its active metabolite, psilocin. Psilocin acts as a partial agonist, primarily at the serotonin 5-HT2A receptor, which is considered central to its psychedelic effects. The pharmacokinetics involve rapid absorption, with effects typically beginning within 20 to 40 minutes, peaking after 60 to 90 minutes, and lasting 4 to 6 hours. The compound is metabolized in the liver by enzymes such as monoamine oxidase and is excreted renally.

Natural sources and history

Psilocybin is biosynthesized by fungi in the genera Psilocybe, Panaeolus, Inocybe, and Gymnopilus, among others. Iconic species include Psilocybe cubensis and Psilocybe semilanceata. Evidence of its use dates back millennia, with possible mushroom stones found in archaeological sites in Guatemala. It was integral to religious and divinatory ceremonies among indigenous peoples such as the Aztec, who referred to the mushrooms as *teonanácatl*, or "flesh of the gods." The modern Western world was introduced to these substances through the work of R. Gordon Wasson, who participated in a velada ceremony with Mazatec curandera María Sabina in 1955. The active compounds were first isolated and identified in 1958 by chemist Albert Hofmann at the Swiss pharmaceutical company Sandoz.

Effects and mechanisms of action

The subjective effects of psilocybin, mediated by psilocin, are highly variable and depend on set and setting. They can include visual and auditory alterations, synesthesia, ego dissolution, emotional lability, and profoundly meaningful introspective experiences. Neurobiologically, activation of the serotonin 5-HT2A receptor on cortical pyramidal neurons leads to increased glutamate release and altered communication within key brain networks. Functional magnetic resonance imaging studies, such as those conducted at Imperial College London, show that the compound decreases activity in the default mode network, a system associated with self-referential thought. This disruption is theorized to underlie the sense of ego loss and increased cognitive flexibility.

Therapeutic research and uses

A resurgence of regulated clinical research began in the 1990s, pioneered by institutions like the Heffter Research Institute. Contemporary trials, often using a supported psychotherapy model, have shown significant promise. Landmark studies from Johns Hopkins University and New York University have demonstrated substantial and sustained reductions in anxiety and depression in patients with life-threatening cancer. The U.S. Food and Drug Administration has granted Breakthrough Therapy designation for psilocybin-assisted therapy for both treatment-resistant depression and major depressive disorder. Ongoing research is exploring its efficacy for conditions including obsessive-compulsive disorder, substance use disorders like alcohol and tobacco dependence, and cluster headaches.

Legal status and regulation

Globally, psilocybin is listed under Schedule I of the United Nations Convention on Psychotropic Substances of 1971, denoting a high potential for abuse and no accepted medical use. In the United States, it is classified as a Schedule I controlled substance under the Controlled Substances Act. However, changing attitudes have led to decriminalization or deprioritization of enforcement in several U.S. jurisdictions, including Denver, Oakland, and the state of Oregon, which passed Measure 109 to create a regulated psilocybin therapy program. Similar reform movements are active in countries like Canada and the United Kingdom. Regulatory bodies like the FDA and the European Medicines Agency are engaged in evaluating data from clinical trials to determine future medical approval pathways.

Category:Psychedelic drugs Category:Tryptamines Category:Entheogens